Wyeth Submits NDA And MAA For Torisel™ For The Treatment Of Advanced Renal Cell Carcinoma - First MTOR Inhibitor To Be Submitted For Cancer Indication

... Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the Company has initiated its global filing strategy for Torisel™ (temsirolimus) with the simultaneous submissions of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMEA). [click link for full article] ...